Prophylactic use of the drug haloperidol does not help to prevent delirium in intensive care patients or improve their chances of survival. Therefore, there is no reason anymore to administer the drug as a preventive measure to reduce the burden of delirium. This was revealed following a three-year, large-scale study among 1,800 patients in 20 Dutch ICUs, headed by Radboud university medical center. The results of this world’s largest research project into delirium prevention in the ICU have been published on February 20 in the Journal of the American Medical Association (JAMA).Acute confusion, or delirium, occurs in approximately one third to half of all patients in the intensive care unit (ICU), and hasserious short-term and long-term consequences. Patients who develop delirium need mechanical ventilation for a longer time and their stay in the ICU and in the hospital is also longer. Also, patients with delirium are more likely to die compared to patients without delirium. If a patient develops delirium, the drug haloperidol is often used to treat it.
There were indications that haloperidol could be effective not only to treat, but also to prevent delirium. A large-scale trial, headed by Mark van den Boogaard from the Radboud university medical center, was conducted in 20 Dutch ICUs to investigate if prophylactic use of haloperidol could reduce delirium and its consequences. A total of 1,800 ICU patients with a high risk of delirium were included in this trial and received a low dose of haloperidol, or a placebo. This trial, funded by ZonMw (the Netherlands Organisation for Health Research and Development), is worldwide the largest trial in this field.
As mortality rates among patients with delirium are higher, the researchers tried to find out whether using prophylactic haloperidol would reduce the mortality and delirium and its sequelae.
The conclusions of this trial were crystal clear: prophylactic therapy with haloperidol did not affect any of the endpoints being studied. Principal investigator Mark van den Boogaard: “This large-scale study shows indisputably that use of prophylactic haloperidol in ICU patients has no beneficial effects whatsoever. These findings will lead to fewer unnecessary drugs being prescribed to ICU patients.”
Head of the research, Professor Peter Pickkers: “The scope of the study and the fact that the results are so unambiguous make the message from our research abundantly clear: there is absolutely no point in administering haloperidol to ICU patients as a preventive measure.”
This research is conducted within the theme Healthcare improvement science.
Related news items
Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis25 January 2021
Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.read more
Oral health research makes significant impact at the 148th WHO Executive Board meeting25 January 2021
During the 148th session of the World Health Organization (WHO) Executive Board meeting, Member States passed a game-changing resolution on oral health. WHO Director General Dr Tedros Adhanom Ghebreyesus called it a “landmark resolution”.read more
Radboud Young Academy safeguards the future of science21 January 2021
New platform to provide advice on policy, create an interdisciplinary network of early career scientists, and promote career development.read more
Increase radio- and immunotherapy efficacy by targeting hypoxia21 January 2021
In a paper recently accepted by Clinical Cancer Research, Daan Boreel, together with Paul Span, Sandra Heskamp, Gosse Adema and Jan Bussink, reviews the therapeutic potential of decreasing the lack of oxygen (hypoxia) often found in solid tumors.read more
Radiation boost lowers risk of prostate cancer recurrence21 January 2021
An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.read more
New research through grants for Radboudumc researchers14 January 2021
Several researchers at the Radboudumc have received grants to start new studies, including on rare diseases, liver disease and cancer metastases. These are grants from the Dutch Research Council, European Joint Programme on Rare Diseases and the Gastric Liver Disease Foundation.read more